{"schema_version":"secwatch.filing_event.v1","accession":"0001816590-25-000103","form_type":"8-K","ticker":"CMPS","cik":"0001816590","company_name":"COMPASS Pathways plc","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.095851+00:00","generated_at":"2026-05-17T22:26:42.721361+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Compass Pathways reports Q2 2025 net loss $38.4M; COMP360 Phase 3 trial hits primary endpoint","bullets":["Positive Phase 3 COMP005 trial: primary endpoint met with high statistical significance and clinically meaningful reduction in depression symptoms at 6 weeks for COMP360 in TRD.","Second pivotal Phase 3 (COMP006) enrolling well; 26-week data expected H2 2026.","Exploring accelerated filing pathway for COMP360 in TRD; DSMB found no safety concerns in Phase 3 studies.","Net loss $38.4M (Q2 2025) vs $38.1M (Q2 2024); net loss per share $0.41 vs $0.56.","Cash $221.9M at June 30, 2025; cash runway into 2027; FY2025 net cash used in ops guidance $120-145M."],"urls":{"canonical":"https://secwatch.observer/filing/0001816590-25-000103","json":"https://secwatch.observer/filing/0001816590-25-000103.json","markdown":"https://secwatch.observer/filing/0001816590-25-000103.md","text":"https://secwatch.observer/filing/0001816590-25-000103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816590/000181659025000103/0001816590-25-000103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816590/000181659025000103/cmps-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:26:42.721361+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}